NCT00123890终止3 期
A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 Infected, Treatment-experienced Subjects With Drug-resistant Virus or an Observational Study.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 试验地点
- 43
- 主要终点
- Determination of subject eligibility for CCR102709, CCR104456, CCR104458, or CCR104629.
研究概览
简要总结
The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.
研究设计
- 研究类型
- Interventional
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-infected.
- •Screening viral load at least 5000copies/mL.
- •Total prior antiretroviral experience of at least 3 months and documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI), stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening.
- •Able to receive a ritonavir-boosted protease inhibitor during treatment studies.
- •Women of childbearing potential must use specific forms of contraception.
- •Exclusion criteria:
- •Acute laboratory abnormalities.
- •History of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any chronic liver disease. Screening liver function tests will be used to determine eligibility.
- •Changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of treatment or observational studies.
- •Pregnancy or breastfeeding women.
- •Recent participation in an experimental drug trial.
- •Prior use of a CCR5 or CXCR4 antagonist.
- •Significant ECG abnormalities or significant history of active pancreatitis, hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe illness.
- •Current use of certain medications may exclude participation in this study.
- •Additional qualifying criteria and laboratory test requirements to be assessed by study physician.
排除标准
- 未提供
结局指标
主要结局
Determination of subject eligibility for CCR102709, CCR104456, CCR104458, or CCR104629.
次要结局
未报告次要终点
研究者
研究点 (43)
Loading locations...
相似试验
已完成
不适用
Eligibility Screening for National Institute of Dental and Craniofacial Research StudiesFibromyalgiaNCT00001983National Institute of Dental and Craniofacial Research (NIDCR)300
已完成
不适用
Pompe Gene Therapy- Screening for EligibilityPompe Disease (Late-onset)NCT03285126Duke University19
已完成
不适用
Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial HypercholesterolemiaHypercholesterolemia, FamilialNCT03018678University of Pennsylvania21
已完成
不适用
A Screening Study Targeting Tumor-specific AntigensMetastatic Colorectal CancerStage II/III Colon CancerNCT05158621Gritstone bio, Inc.22
已完成
不适用
Potential Research Participants for Future Studies of Inherited Eye DiseasesGlaucomaRetinitis PigmentosaCataractStrabismusMacular DegenerationNCT00559234National Eye Institute (NEI)400